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Abstract
Background: Cell-free residual HIV-1 virions (RVs) persist in plasma below 20–50 vRNA copies/ml in most patients
on suppressive antiretroviral therapy (ART). How RVs are produced in the body during therapy is not fully clear.
In this study, we have attempted to characterize these viruses of an ART-treated patient in vitro in order to gain
insights into the mechanism of their production in vivo.
Methods: We have reconstructed almost the entire genomes of RVs as DNA forms using the patient’s residual
plasma vRNA by an overlapping RT-nested PCR method, and then sequence-analyzed the cloned genomes and
tested them for their biological activities in vitro.
Results: We found that the reconstructed molecular clones of RVs lacked antiretroviral drug-resistant mutations,
as well as G-to-A hypermutations. The vDNA clones, when transfected into TZM-bl cells, released HIV-p24 into the
culture media at extremely low levels. This low-level virus production was found to be due to the presence of a
unique mutation (GU-to-GC) in the conserved 5′-major splice donor (MSD) motif of the corresponding vRNAs.
We found that the incorporation of this point mutation by itself could cause defects in the replication of a standard
HIV strain (JRCSF) in vitro. However, this novel viral variant was intermittently detected at 5 of 7 time-points in the
patient’s plasma over a period of 39 months during therapy.
Conclusions: This is the first identification of a natural point mutation (GU-to-GC) in the conserved 5′-MSD motif of HIV
genomic RNA. The intermittent but prolonged detection of this replication-defective HIV variant in the patient′s plasma
among other viral populations strongly suggests that this variant is released from highly stable productively infected
cells present in vivo during therapy. The potential implication of this observation is that the elimination of such
productively infected cells that contribute to residual viremia during suppressive therapy could be an important first
step towards achieving a cure for HIV.
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Background
Current ART suppresses plasma viral loads to levels
below the limit of detection in clinical viral load assays,
generally 20–50 HIV RNA copies per ml of plasma [1].
This suppressed viral load status remains stable as long
as patients continue therapy with high adherence [2].
However, ultrasensitive laboratory-based techniques can
detect very low amounts of vRNA circulating in plasma
below the clinical detection limit in most patients on
prolonged ART [3–9]. These low viral loads in plasma
during therapy are referred to as residual viremia. The
cell- or tissue source of the corresponding viruses (i.e.,
RVs) or their mechanism of production is still not fully
clear.
A notion is that RVs are produced due to incomplete
inhibition of viral replication by ART in the lymphatic
tissues where antiviral concentrations appear suboptimal
[10]. The process of continuous cycles of viral infection,
integration, and production from target cells is referred
to here as viral replication. However, viral variants
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resistant to antiretroviral drugs do not usually emerge in
patients with high adherence to prolonged suppressive
therapy [11–13]. Also, the levels of residual viremia were
not affected by therapy intensification [14], even with
the inclusion of an integrase inhibitor to the antiretro-
viral regimen [15–18]. Although some studies had ob-
served transient increase in the levels of 2-LTR circles in
a portion of patients who received raltegravir-based ther-
apy intensification, and suggested the occurrence of viral
replication at low levels during therapy [19, 20], others
found no such increase in 2-LTR circles, contradicting
the possibility of RV production as a result of ongoing
replication during therapy [21]. Overall, these conflicting
observations led to an alternative postulate that highly
stable, productively infected cells may exist in lymphoid
tissues or some bodily locations, where they persistently
release virus particles during effective therapy [14, 22, 23].
Such reservoir was recently named as the active HIV
reservoir [24], but direct evidence behind the postulate is
still lacking.
To understand the mechanism of how RVs appear in
plasma during therapy, we sought to molecularly clone
these viruses, and then study their biology in vitro. Ac-
cordingly, we reconstructed eight RV clones from an
ART-treated patient’s plasma vRNA by adapting a proto-
col published previously [25]. We found that the vDNA
clones could secrete HIV-p24 in media upon transfec-
tion into a human cell line (TZM-bl), but the levels were
much lower compared to the levels produced by the
standard HIVJRCSF clone [26], or by our previously pub-
lished RV clone, C1P [25]. The presence of a unique mu-
tation (GU-to-GC) in the conserved 5′-major splice
donor (5′-MSD) motif of genomic vRNA was found to
be a cause for diminished viral p24-production from RV
clones. The known antiretroviral drug-resistant muta-
tions as well as G-to-A hypermutations were absent in
these clones. Interestingly, we could intermittently de-
tect the unique viral 5′-MSD variant in the patient’s
plasma over a period of 39 months during therapy, im-
plicating that its source in the body remained highly
stable and capable of producing virus at low levels dur-
ing suppressive ART, contributing to residual viremia.
Methods
Study patient
A white (non-Hispanic) 57-year-old male HIV+ patient
(identified here as patient G) effectively treated with
ART in the RWMC clinic was recruited in November
2012 for an HIV-1 reservoir study. He signed a consent
form approved by the Institutional Review Board to par-
ticipate in the study. During each visit to the study every
3 to 7 months, his plasma viral load was measured and
he was asked to donate 50 ml of blood. Initially, for a
period of 16 months, a total of five blood samples (G1 to
G5 in Fig. 1) were collected from him, and about a year
after the 5th visit, three more blood samples (G6 to G8)
were collected (Fig. 1), accumulating a total of 8 samples
over the study period of 42 months.
Blood sample processing
Each sample was immediately processed after collection
through Ficoll-hypaque method as described previously
[27]. Plasma virus particles were pelleted by ultracentri-
fugation, followed by vRNA isolation as previously per-
formed [25, 28] using a vRNA isolation kit (Qiagen).
The isolated plasma vRNAs were designated sequentially
as G1P, G2P, etc., as they were isolated from blood sam-
ples collected at the 1st visit (G1), 2nd visit (G2), and so
on, respectively (Fig. 1), and then stored at −70 °C for
future use.
Fig. 1 ART-mediated suppression of plasma viral load (VL) in patient G. Plasma VLs were measured by clinical assays with detection limits of 48
(prior to March 2011) or 20 copies/ml; results below the limit of detection were graphed as 47 and 19 copies/ml, respectively. Two VL blips of
297 and 100 copies/ml occurred in January 2011 and May 2016, respectively. Blood samples collected at 1st visit, 2nd visit, and so on in the study
are indicated by G1, G2, etc., respectively
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Isolation and culture of CD4+ T-cells from blood
Whenever required, CD4+ T-cells were isolated from
normal HIV-negative donors’ PBMCs through negative
selection method using the EasySep human CD4+ T-cell
enrichment kit (StemCell, Canada). The isolated cells
were stimulated with Dynabeads human T-activator
CD3/CD28 (ThermoFisher Scientific) by following the
manufacturer’s instructions and cultured in media con-
taining IL-2 (100U/ml) for expansion.
RT-nested PCR, and cloning
Four different fragments spanning almost the entire HIV
genome (Fig. 2a) were amplified by RT-nested PCR, as
previously described [25] and the amplified fragments
are shown in Fig. 2, panels b-d. Twenty-one microliters
of vRNA equivalent to about one-sixth of the total
vRNA isolated from 50ml blood-derived plasma were
used as the template in the first RT-PCR step. For such
low copy number target vRNA amplification, a highly
Fig. 2 Reconstruction of residual plasma HIV-1 genomes as DNA form. Panel a schematically shows the corresponding strategy. The small 337 bp
(R-gag) and 408 bp (U3-R) DNA fragments and the large 3.5 kb, and 5.3 kb fragments were separately amplified by RT-nested PCR using residual
plasma vRNAs as targets. Each horizontal small arrow indicated by A through H represents a pair of primers (Additional file 5: Table S1) used in
the RT-nested PCR. The U3, R and U5 regions are the elements of the HIV-1 long-terminal repeat (LTR). R-gag and U3-R fragments were fused to
generate the U3-gag fragment (not shown), which was later combined with 5.3 kb and 3.5 kb fragments to build the 5′- and 3′-halves, respectively
(see Additional file 1). Panels b, c and d show the amplified fragments (indicated by arrows) in agarose gels. Lanes are marked with the corresponding
fragment names. Lane M shows the GeneRuler 1 kb plus DNA ladder (Thermo Scientific). In panel d, the size difference between the R-gag and U3-R
bands is not reflected in the agarose gel due to anomaly in the migration of DNA bands, but the identity of these bands was verified by sequence
analyses. A 200 bp band seen below the 337 bp R-gag band is not HIV-specific
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sensitive and efficient one-step RT-PCR system that in-
cludes SuperScript III/platinum Taq (Life Technologies)
was employed using the appropriate primer pairs and re-
action conditions (see Additional file 1). After 40 cycles
of PCR, 5 μl of the products were taken as templates in
a 50 μl reaction volume for nested PCR of 35 cycles
using the Expand high-fidelity PCR system (Roche). The
amplified products were eluted from 0.8 % agarose gel
and cloned into pCR-XL-TOPO vector (Life Technolo-
gies) in TOP10 competent cells for sequencing and
analyses.
An overlapping PCR method was performed as previ-
ously described [25] to attach two different amplified frag-
ments as appropriate using the Expand high-fidelity PCR
system (Roche) but after removing any 3′-A overhangs of
amplified fragments with T4 DNA polymerase. The result-
ing fragments were cloned into pCR-XL-TOPO vector
and sequenced to validate the correct fusion of fragments.
Sequence analyses
Nucleotide (nt) sequences were aligned using the
CLUSTAL-W program available in Vector-NTI express
software (Life Technologies), BioEdit or, in MEGA6 pro-
gram [29]. The quality of the full-length viral genomic
sequences was checked by using the QC tool available in
the HIV database of Los Alamos National Laboratory.
Phylogenetic analyses
Residual viral sequences were subjected to phylogenetic
tree reconstruction using the Neighbor-Joining method
[30] in the MEGA6 program [29]. The evolutionary dis-
tances were computed using the Tamura-Nei method
[31] and the rate variation among sites was modeled
with a gamma distribution (shape parameter =1). The
corresponding sequence regions from the standard la-
boratory HIV strains, such as HIVNL4–3 [32], HIV213
[33], HIVJRCSF [26], HIVC1P [25], were included in the
outgroup. The bootstrap test (1000 replicates) was per-
formed [34] and the values are shown next to the
branches.
Transfection of plasmid DNA into TZM-bl cells
These cells [35] were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10 % fetal
bovine serum (FBS), 2 mM L-glutamine and penicillin/
streptomycin. One microgram of plasmid DNA was
transfected into TZM-bl cells in 12-well plate using lipo-
fectamine (Life Technologies) DNA transfection reagent
by following the manufacturer’s instructions. The cul-
tures were incubated in a 5 % CO2 incubator at 37 °C.
The next day, media from the transfected cells was re-
placed with fresh media, and the cultures were contin-
ued for another 24-48 h.
Site-directed mutagenesis
This was performed by using the GeneArt Site-directed
Mutagenesis Kit (Life Technologies). Primers were de-
signed by following the GeneArt designer tool (Life
Technologies), and after every mutagenesis reaction, the
desired change in DNA was confirmed by sequencing.
Sequence deposition into the GenBank
Nucleotide sequences for the reconstructed residual
plasma HIV-1 clones have been submitted to GenBank
under accession numbers KT284371 to KT284378.
Results
Status of clinical viral loads during prolonged ART and
longitudinal sampling of residual plasma vRNA
Patient G was 57 years old in 2012 when he donated his
first blood sample for this study. Based on the available
health records, he started ART in 1991 and had been ef-
fectively treated for HIV infection in the RWMC clinic.
He was treated with the antiretroviral combination,
tenofovir/emtricitabine and nevirapine during the first
year of the study, and then with the current combination
of abacavir sulfate/lamivudine and nevirapine. From
April 2010 to May 2016, his plasma viral loads remained
<50 HIV RNA copies/ml in clinical tests performed
every 2–7 months during his clinic visits, except that he
had two viral load blips of 297 and 100 copies/ml in
January 2011 and May 2016, respectively (Fig. 1). Clin-
ical viral load test results were below the 20 copies/ml
limit of detection in approximatley 75 % of his visits
during the last 5 years, indicating that viremia was ef-
fectively suppressed by the prescribed antiretroviral regi-
men. During this period, his CD4+ T-cell counts/μl of
blood ranged from 608 to 1106.
Reconstruction of the full-length residual HIV genomes
The underlying strategy for this reconstruction was pri-
marily adapted from our previously published report
[25] and is schematically shown in Fig. 2a. Essentially,
four viral genomic fragments were amplified (Fig. 2,
panels b-d) from G4P vRNA by RT-nested PCR (see
methods). Each of the amplified 5.3 kb, 3.5 kb, 337 bp
and 408 bp fragments (Fig. 2a) had an overlapping re-
gion(s) with its neighboring fragment(s). The overlap-
ping regions were exploited to combine the neighboring
fragments either by the overlapping PCR method or by
the restriction enzyme digestion and ligation method as
appropriate in order to reconstruct the full-length vDNA
genomes. For instance, 337 bp R-gag and 408 bp U3-R
fragments were combined through the overlapping PCR
method to generate the U3-gag fragments, which were
also subsequently combined with the 5.3 kb and the 3.5
kb fragments through the same method to build 5′-
and 3′-halves of the viral genome. We took two
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different 5′-halves and combined each with 4 different
3′-halves (Additional file 2: Figure S1) by utilizing the
overlapping EcoN1 sites and generated a total of 8 full-
length residual vDNA clones (namely, RV-1, −1a, −1b,
−1c, −11a, −11b, −11c, and -11d).
The nt sequences of these viral clones were deposited
into GenBank (see methods) and were identified as the
HIV subtype B sequences by using the NCBI HIV sub-
typing tool (http://www.ncbi.nlm.nih.gov/projects/genotyp
ing/formpage.cgi). These viral nt sequences were unique
showing maximum homologies up to 92-94 % with the
existing HIV sequences in the NCBI nt database. The
phylogenetic tree (Fig. 3) constructed by using the
Neighbor-joining method [30] showed that the RV se-
quences clustered together in a branch separated from
those of laboratory standard HIV sequences, suggesting
that the obtained viral sequences were patient-specific,
not laboratory contaminants.
The reconstructed full-length residual vDNAs could
secrete HIV-p24 in media at low levels upon transfection
into TZM-bl cells
To examine whether the viral genomic clones are cap-
able of producing virus in vitro, we transfected vDNAs
into TZM-bl cells in 12-well plate (see methods). For
positive controls, equivalent amounts of the standard
HIVJRCSF DNA and the previously cloned residual
HIVC1P DNA were also transfected into TZM-bl cells
separately. After 48h of incubation, culture supernatants
were tested for the levels of HIV-p24 by enzyme-linked
immunosorbent assay (ELISA). Figure 4 shows that all
residual vDNA clones reconstructed in this study could
produce HIV-p24 in transfected cells, which was se-
creted into the culture media. However, we repeatedly
observed that the levels of secreted HIV-p24 were ~2-
log10 lower than the levels detected with either of the
positive controls, i.e., HIVJRCSF or HIVC1P DNA (Fig. 4).
Although culture media from vDNA-transfected cells
showed marginal levels of infectivity in MAGI assays
[36], the released virions in media were defective for
replication in activated CD4+ T-cells or monocyte-
derived macrophages of normal donors (data not
shown).
Residual viral sequences lacked G-to-A hypermutation as
well as drug-resistant mutation
To investigate the underlying reason for the limited viral
production as well as the replication-defect of the vi-
rions produced from the cloned vDNAs, we sought to
examine whether these clones possess G-to-A hypermu-
tations at statistically significant levels compared with
the standard HIVNL4–3 clone. G-to-A hypermutations
(or transitions) occur in proviral sequences due to the
mutational pressure exerted by the APOBEC-induced
cytosine deamination on nascent viral cDNA during
reverse-transcription in the infected cells [37–39]. An
excess of such mutations, including premature stop
codon generation in the viral ORFs [40, 41], results in
viral replication defects. Although the viral Vif counters
the negative effects of APOBEC proteins on the virus in
host cells [42], G-to-A hypermutations still occur in pa-
tients’ PBMC-associated proviral sequences [43]. Upon
analyses of the full-length residual vDNA sequences
using the Hypermut 2.0 program [44] available in the
Los Alamos National Laboratory (LANL) website, we
found that none of the eight clones had G-to-A hyper-
mutations when compared with the standard HIVNL4–3
sequence (Fisher’s exact P-values range from 0.91 to
0.95, where P < 0.05 would indicate hypermutation).
These data indicate that the cloned RVs were devoid of
hypermutations; this observation is in agreement with a
previously published report [40]. By using the QC tool
available in the LANL, we found that all the viral open
reading frames (ORFs) in these full-length clones were
also intact. Overall, these data suggest that the detrimen-
tal mutations did not accumulate to account for HIV
clones’ low viral productivity or replication defects in
vitro.
Since the vDNA clones were derived from vRNA iso-
lated from plasma during suppressive therapy, an obvi-
ous question arises whether the cloned RVs possessed
ART-resistant mutations for which they were able to
somehow replicate in vivo at low levels during therapy.
We found none of the viral pol ORFs possessed any of
the drug-resistant mutations listed in the Stanford Uni-
versity’s HIV Drug Resistance Database, suggesting that
the cloned RVs represent drug-sensitive viruses circulat-
ing in plasma during therapy.
Fig. 3 Phylogenetic analyses of RV sequences derived from eight
reconstructed clones. Viral sequences (~9.6 kb each) were subjected
to phylogenetic tree reconstruction by using the Neighbor-Joining
method. Bootstrap values greater than 70 % are shown. HIV-NL4-3,
HIV-213, HIV-JRCSF and HIV-C1P represent the standard HIV strains
used in the laboratory
Rassler et al. Virology Journal  (2016) 13:157 Page 5 of 13
A novel mutation identified in the conserved 5′-MSD site
of vRNA caused limited HIV-p24 production from residual
vDNA clones
We sought to compare residual vDNA sequences with
those of three standard strains (HIV213, HIVNL4–3 and
HIVJRCSF) in the CLUSTAL-W program [45] to identify
any unique mutations present in the residual vDNA
clones, which could potentially be associated with the
low p24-production phenotypes of these clones. Among
many sequence changes, strikingly, we observed a single
nt mutation (GT-to-GC) present in the 5′-MSD motif of
each RV clone (Fig. 5a), which was not previously
Fig. 4 Limited levels of HIV-p24 production from all residual vDNA clones. TZM-bl cells were transfected separately with eight reconstructed
vDNA clones in duplicate, and after 48 h, HIV-p24 levels in culture media were quantified by ELISA (Advanced Bioscience, Inc.). A standard HIV
(JRCSF) DNA and our previously published residual vDNA clone (C1P) were used as positive controls for virus production in these assays. Error bars
represent standard deviations (s.d.). Results were compared with the positive control C1P using unpaired t-test; asterisk (*) indicates p < 0.05
Fig. 5 Analyses of viral genomic region containing 5′-MSD motif. a The presence of a unique GT-to-GC mutation at the 5′-MSD motifs of residual
vDNA clones. Only a region spanning the 5′-MSD junction was taken from each vDNA sequences and aligned with the corresponding sections of
the three standard HIV strains (top). The 5′-MSD motif mutation (GT-to-GC) in each vDNA clone is shown within the vertical box. b Illustration of
the conserved splicing motifs present in HIV genomic RNA. Bold underlined GU, A and AG represent 5′-major splice donor (5′-MSD) site, branch-
point, and a 3′-splice acceptor sites (3′-SA), respectively. Generally, such sites are also utilized during mRNA splicing in eukaryotes. The R and U5
regions belong to the HIV long-terminal repeat (LTR). The ‘non-coding exon 1’ is always combined with the polyadenylated [poly(A)] ‘exonic’
portion of vRNA upon splicing
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reported for HIV in nature. However, the artificial muta-
tion of GT-to-CA at the 5′-MSD motif of the standard
HIVNL4–3 clone was previously shown to cause lower ef-
ficiencies of vRNA splicing in the transfected HeLa cells,
resulting in ~6-fold lower levels of viral progeny forma-
tion compared to the levels observed with the wild-type
virus [46]. The importance of the 5′-MSD motif in
HIV-1 biology is briefly mentioned in the discussion
section, but the conserved motifs for splicing are illus-
trated in Fig. 5b.
To examine whether the natural GT-to-GC mutation
at the 5′-MSD site of our cloned vDNAs caused limited
HIV-p24 production in transfected cells, we reverted the
GC dinucleotide back to the wild-type GT form at the
5′-MSD sites of four vDNA clones (i.e., RV-1, −1a, −1b,
and -1c) by site-directed mutagenesis (see methods). The
resulting vDNA clones were labeled as RV-2a, −2b, −2c
and -2d (Fig. 6a). Upon transfection into TZM-bl cells, we
found that these new vDNA clones (RV-2a to RV-2d) with
the wild-type 5′-MSD motif could produce on average
~20 to 30-fold higher levels of HIV-p24 than their re-
spective parental clones with mutated 5′-MSD motif
(Fig. 6a), suggesting that the 5′-MSD motif mutation did
play a significant role in the limited production of HIV-
p24 from the original vDNA clones.
To further substantiate the above observation, we in-
corporated GT-to-GC mutation at the 5′-MSD motif of
the standard HIVJRCSF clone by site-directed mutagen-
esis; the levels of p24 production from the resulting mu-
tant clone in transfected cells were then compared with
those of the wild-type counterpart. We found that the
5′-MSD mutated HIVJRCSF clone could produce ~42-
fold lower levels of HIV-p24 than the wild-type clone
(Fig. 6b); however, the mutant virus could not replicate
in activated CD4+ T-cells in vitro (Fig. 6c). These data
demonstrated that the 5′-MSD motif mutation in the
original reconstructed vDNA clones was responsible for
reduced HIV-p24 production in the transfected TZM-bl
cells, and the mutation by itself could impede viral repli-
cation in activated CD4+ T-cells in vitro.
As mentioned above, the GT-to-CA mutation (two-nt
change) at the 5′-MSD motif of HIVNL4–3 was previ-
ously reported to cause low efficiencies of vRNA splicing
in HeLa cells [46], and also, the mutant virus was found
to utilize a cryptic splice donor GT (GU for RNA) site
located 4 nt downstream of the original 5′-MSD GU
motif for vRNA splicing (see Fig. 5b). To examine
whether the single nucleotide change (GT-to GC) in the
5′-MSD motif of the cloned RVs and HIV-JRCSF can
affect vRNA splicing, we transfected a RV 5′-MSD mu-
tant (RV-1) clone and its wild-type counterpart (RV-2a),
as well as JRCSF and JRCSF-MSD clones, into TZM-bl
cells separately (see Additional file 1). Forty-eight hours
later, we found that RV-1- and JRCSF-MSD-transfected
cells showed much reduced levels of spliced viral tat
mRNA, compared to RV-2a and JRCSF-transfected cells
(Fig. 6d), respectively. Furthermore, the viral mutants
could utilize the GU site located 4nt downstream of the
original 5′-MSD GU site for low-level vRNA splicing
(Additional file 3: Figure S2), as similar to the NL4-3
mutant [46]. These data suggest that the single nucleo-
tide mutation (GT-to GC) at the 5′-MSD motif of HIV
can also lower vRNA splicing efficiencies in vitro, and
provide an explanation for why limited levels of HIV-
p24 are produced by 5′-MSD mutated vDNAs, in com-
parison to their wild-type counterparts, in transfected
cells (Fig. 6a and b).
Viral 5′-MSD mutant was intermittently detected in the
patient’s plasma for a prolonged period during therapy
The isolation of replication-defective RV 5′-MSD mu-
tant from the ART-treated patient’s plasma at his 4th
visit led to a possibility that some productively infected
cells persisting in the body were able to express the de-
fective virions and release them into plasma, even in the
presence of therapy. Such infected cells releasing virus
during therapy were previously predicted to exist in vivo
[14, 22, 23] and recently termed as the active reservoir
of HIV [24], which was also thought to remain highly
stable in the body and contribute to residual viremia
during therapy. If 5′-MSD variant was released into
plasma from such a stable virus-expressing reservoir,
one would expect to detect the same 5′-MSD variant in
plasma at different time points over a prolonged period.
To examine this possibility, we amplified the R-gag
fragments containing the 5′-MSD motif from other
longitudinally-collected plasma vRNA samples (i.e.,
G1P-, G2P-, G5P- to G8P-vRNAs) by RT-nested PCR
(Additional file 4: Figure S3) and sequence-analyzed them.
We found that the 5′-MSD variant could be detected in 5
out of 7 plasma samples analyzed (Table 1); the interval
between the first and the last detection was about 39
months (Table 1). The viruses with wild-type 5′-MSD
motif were also detected along with the variant in most (6/
7) samples (data not shown in Table 1). However, the
prolonged but intermittent detection of the replication-
defective viral 5′-MSD variant in plasma strongly suggests
that at least this variant was released from a cellular source
that remained extremely stable in the body during therapy.
Discussion
Residual plasma viremia persists in most patients below
the clinical detection limit, even after prolonged sup-
pressive therapy [3–9]. The clinical significance and the
cellular source of this low-level viremia are still not fully
clear. HIV is known to persist in various cellular or tis-
sue reservoirs in ART-treated patients, from where it
can disseminate infection in the body when the therapy
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is stopped, resulting in viral load rebound in plasma
within a few weeks [47]. By virtue of viral expression sta-
tus, HIV reservoirs can be classified into two categories:
one as the ‘latent reservoir’ [48], and the other as the ‘ac-
tive reservoir’ [24]. The latent reservoir classically con-
sists of resting memory CD4+ T-cells carrying proviral
DNA in a dormant state. While this reservoir can pro-
duce virions only after cell-activation [49], previous
studies had undermined its contribution to persistent re-
sidual viremia during therapy upon analyzing patients’
blood samples, and proposed the existence of an un-
known source in vivo for such low-level viremia [28, 50].
Recently, it was hypothesized that this unknown reser-
voir (namely, the active reservoir) remains highly stable
in vivo and persistently produces virions at low levels
during therapy, as opposed to the latent reservoir [24].
Fig. 6 Increased HIV-p24 production from vDNA clones with wild-type 5′-MSD motif. a The GC-to-GT reversion at the 5′-MSD motif of residual
vDNA clones improved viral p24 production. Equivalent amounts of vDNAs were transfected into TZM-bl cells, and 48h later, HIV-p24 levels in
culture media were quantified by ELISA. C1P, a standard residual HIV-1 clone, was used as a positive control. mt-MSD and wt-MSD represent RV
clones with mutated 5′-MSD and their wild-type counterparts, respectively. Error bars represent s.d., n = 4. The statistical significance of the data
was calculated by using unpaired t-test; asterisk (**) and (***) indicate p < 0.002 and p < 0.0001, respectively. b Reduced HIV-p24 production from
the standard HIV-JRCSF clone with 5′-MSD motif mutation. GT-to-GC mutation was incorporated at the 5′-MSD motif of HIV-JRCSF clone by site-
directed mutagenesis. Equal amounts of the wild-type (JRCSF) and the mutant (JRCSF-MSD) vDNA clones were transfected into TZM-bl cells in
triplicate, and 48h later, the levels of p24 production in culture media were measured by ELISA. Error bars represent s.d. The statistical significance
of the data was calculated using unpaired t-test. Asterisks (***) denote p < 0.0005. c Replication defect of JRCSF-MSD mutant in stimulated CD4+
T-cells. HIV-JRCSF and JRCSF-MSD viruses were freshly prepared by transfecting their DNA clones into TZM-bl cells, followed by harvesting culture
media after 48h. About 1x106 of freshly stimulated CD4+ T-cells from a normal donor were infected overnight in triplicate in 24-well plate with
the equivalent amounts of these viruses (1200 pg of p24 each). Next day, infected cells were washed three times and cultured in media containing
100 u/ml of IL-2. Culture supernatants were harvested on days indicated and tested for the levels of HIV-p24 by ELISA. Error bars represent s.d.
d Low-levels of spliced vRNA produced by 5′-MSD mutated vDNAs. Total RNA isolated from TZM-bl cells transfected equivalently with various
vDNA clones were used as template for RT-PCR amplification of HIV transcripts. RV-1 and RV-2a represent residual HIV clones with mutated
and wild-type MSD motifs, respectively. Panels are labeled to the left with the corresponding amplified products. Lane M denotes GeneRuler plus
DNA ladder
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Viral production is referred to here not as viral replica-
tion that occurs through complete cycles of infection, in-
tegration and production of progeny virions; but rather
simply as spontaneous viral synthesis and release from
already infected cells, even in the presence of therapy.
The existence of such a reservoir in patients is generally
difficult to prove, especially in light of a recent report by
Lorenzo-Redondo, et al. [13] describing that viral repli-
cation continues in tissues where antiretroviral drug
concentrations are suboptimal. The authors also pro-
posed that under low ART-pressure, the evolution of
drug resistance is greatly diminished by replication fit-
ness advantages of wild-type viruses over drug-resistant
variants colocalized in the tissue compartments, provid-
ing an explanation for why drug-resistant viral variants
do not usually emerge in patients on prolonged suppres-
sive therapy.
The residual vDNA clones that we have reconstructed
from the patient’s plasma vRNA isolated at G4 (Fig. 1)
did not possess any antiretroviral drug-resistant muta-
tion or G-to-A hypermutations, and had all viral ORFs
intact. However, the virions released from vDNA-
transfected cells could not replicate in activated CD4+
T-cells or monocyte-derived macrophages of normal do-
nors (data not shown). The absence of viral replication
in vitro indicates that the reconstructed vDNAs re-
presented replication-defective cell-free RVs that were
circulating in patient G’s blood during his 4th visit to the
study. Upon investigation, we found that all vDNA
clones had a unique GU-to-GC mutation at the 5′-MSD
motifs of the corresponding viral genomic RNAs, and
the reversion of this mutation to wild-type led to signifi-
cantly increased levels of HIV-p24 production in the
transfected TZM-bl cells, validating that this mutation
limits HIV expression (Fig. 6a).
The 5′-MSD motif is one of the four splicing donor
(SD) sites in the HIV-1 RNA genome, which remains
highly conserved and is constitutively used during the
processing of full-length vRNA through splicing to gen-
erate over 40 different viral mRNA species [46, 51–53].
There are about 8–11 3′-splice acceptor (SA) sites in the
viral genome [52, 53]. In the RNA splicing mechanisms,
the cellular spliceosome cleaves at exon-intron junctions
through trans-esterification reactions [54–56], typically
right before the GU dinucleotide (underlined) at the 5′-
MSD site (CUGGUGAGUA), and right after the AG
dinucleotide at the 3′-SA sites in vRNA to remove in-
tronic portion (see Fig. 5b). The noncoding exon 1 span-
ning upstream of the 5′-MSD site is always included
with all spliced forms of vRNA [53]. Generally, the GU
dinucleotide motif at the mRNA splice donor site is well
conserved across the species and possessed by ~98 % of
introns [57, 58], but the mutations at this site are known
to affect mRNA splicing negatively in vitro [59, 60].
The 5′-MSD mutation (GT-to-GC), to our knowledge,
has not been previously reported for HIV in the natural
context. While we could detect this mutation in patient
G’s plasma frequently (5 of 7 occasions), we failed to de-
tect the same mutation in residual plasma vRNAs of
three other patients (not shown) on suppressive therapy,
suggesting that the 5′-MSD mutation in HIV infection
may occur rarely. The introduction of the same 5′-MSD
mutation (i.e., GT-to-GC) in the standard HIV strain
(JRCSF) was found to diminish viral RNA splicing
(Fig. 6d) and gene expression severely (Fig. 6b), and the
viral mutant (JRCSF-MSD) could not replicate in acti-
vated CD4+ T-cells of normal donors (Fig. 6c), which
strongly suggests that the RV 5′-MSD variant remains
replication-defective in vivo. Therefore, the 5′-MSD mu-
tation should not offer the virus a selective advantage in
vivo, except that the down-modulation of viral gene ex-
pression caused by the mutation may facilitate the host
cells to survive in vivo by avoiding viral cytopathic ef-
fects as well as host immune clearance mechanisms.
Interestingly, the defective variant was detected in the
patient’s plasma at 5 out of 7 time-points that spanned
over 42 months during the study (Table 1), suggesting
that its cellular source persisted long-term in the body
during suppressive therapy and released virions in
plasma at low levels, contributing to residual viremia.
The low-level production and thereby shedding of 5′-
MSD variant into plasma from a source cannot be con-
fused with ‘cryptic’ viral replication (which is suspected
to occur in tissues during therapy [13]), because the 5′-
MSD mutation by itself could impede viral replication,
even if other viral components remained intact (Fig. 6c).
Instead, the long-term detection of replication-defective
5′-MSD mutant in plasma during suppressive therapy
should reveal that some highly stable infected cells exist-
ing in the body are able to express virions at low levels
at the single cell-level and release them into plasma,
even in the face of therapy without experiencing viral
Table 1 Prolonged detection of viral 5′-MSD variant in plasma during therapy
Plasma vRNA (sample ID) G1P G2P G3P G4P G5P G6P G7P G8P
Collection date Nov. 13, 2012 Feb. 12, 2013 July 23, 2013 Oct. 28, 2013 Mar. 11, 2014 Apr. 21, 2015 Nov. 24, 2015 May 20, 2016
Detection of RV 5′-MSD
variant
no yes nd yes no yes yes yes
Days since first detection −91 0 258 798 1015 1193
‘nd’ indicates ‘not done’
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replication events at the cell-population levels. As men-
tioned earlier, such stable HIV-infected cells releasing
virus were previously predicted to exist in vivo during
therapy [14, 22–24]; however, direct evidence to support
this hypothesis was largely lacking. We believe that our
data demonstrating the prolonged persistence of the
replication-defective 5′-MSD variant in the patient’s
plasma during therapy serves as evidence for the exist-
ence of stable HIV-producing cells (namely, the active
reservoir) in vivo. It is worth noting that we could also
detect viruses with wild-type 5′-MSD motif in all plasma
samples of the patient, except in one, which indicates
that residual plasma viruses may not be all genetically
defective but could be a mixture of particles carrying
replication-defective and -competent genomic RNAs, as
previously reported [25].
Although we cannot rule out the possibility that re-
sidual viremia may partly emanate from ‘cryptic’ viral
replication occurring in tissues during therapy [13], the
replication fitness advantage model proposed by these
authors does not fit with the appearance of replication-
defective 5′-MSD variant in the patient’s plasma in our
study. How this viral variant was produced is not clear,
but the underlying mechanisms may shed light on the
very nature of the source of residual viremia persisting
during therapy. Based on the intermittent detection of
5′-MSD variant in plasma below the clinical detection
limit, as well as the published data by others [61], we
propose a model (Fig. 7b) illustrating how RVs might be
produced from a source in vivo. It is known that the
current ART does not block virion-production or -re-
lease from the cells that are already infected and remain
in the productive phase of infection. A stable pool of
infected cells residing in tissues at low frequencies may
actively release virions at low levels over time, giving rise
to residual viremia during therapy. While these cells
may not usually circulate in blood [28, 50], they could
be clonally expanded in tissues, like latently infected
CD4+ T-cells [62, 63], to form cell lineages carrying
genetically distinct but phylogenetically related proviral
species [64]. Recently, the detailed analyses of a highly
expanded CD4+ T-cell clone carrying infectious proviral
DNA (namely, AMBI-1) at the same integration site was
reported [65]. This clone was identified in an HIV-
infected patient who had squamous cell carcinoma.
Although the clonal cells were detected in blood, as well
Fig. 7 Status of HIV expression in different reservoirs. a Latent reservoir. HIV is not usually expressed, but upon cell-stimulation, only a fraction
of inducible latent proviruses residing in resting memory CD4+ T-cells (shown in blue) can be reactivated to express virus in the presence or
absence of ART. b Active reservoir. A model for RV-production from a pool of infected ‘semi-quiescent’ cells (shown in yellow) representing an
expanded cell clone is illustrated here. Virus production may occur spontaneously in waves over time with or without ART. Such multiple clonally
expanded infected cell lineages in tissues may simultaneously release virions during therapy, each contributing to residual viremia
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as in lymphoid tissues, they were found enriched in
metastatic lesion. Importantly, the AMBI-1 virus was
persistently detected among residual virus populations
circulating in plasma for more than 3 years, suggesting
that the virus was released into plasma by this expanded
clone for such a prolonged period [65]. We believe each
of such highly stable infected cell lineages present in the
body can release virions at low levels in waves over time
(Fig. 7b), as observed by others in gut-associated lymph-
oid tissues of humanized mouse model of HIV infection
[61], contributing to residual viremia during therapy.
The activation state of these cells may remain confined
in-between the resting and the fully activated states,
allowing the virus to be expressed at low levels. The gen-
eration of such ‘semi-quiescent’ CD4+ T-cells persist-
ently producing HIV at low levels for a prolonged period
was previously observed in our H80 model of HIV la-
tency [27]. It is not clear whether such low-level virus-
expressing cells usually die in vivo, as proposed recently
[66], or whether they persist as highly stable chronic
virus producers during therapy. In our study, the reser-
voir expressing RV 5′-MSD variant is found to live in
the patient for at least 39 months (Table 1), which sug-
gests that such virus-expressing reservoir remains ex-
tremely stable in vivo. If the majority of RVs in treated
patients’ plasma are released from stable HIV-producing
cells (i.e., active reservoir) as similar to the 5′-MSD vari-
ant in our study, then therapy intensifications should
not have any effect on the levels of residual viremia, as
observed previously [14–18]. In contrast, the latent res-
ervoir that consists of long-lived resting memory CD4+
T-cells carrying dormant but replication-competent pro-
viral DNA requires cell-stimulation for virus production
[49] (Fig. 7a). However, the majority of these proviral
DNAs remain refractory to even optimal cell-activation
in vitro [67].
A limitation of our study is that the cloned RVs could
not replicate in stimulated blood CD4+ T-cells of nor-
mal donors, unlike in our previous study [25], even
when the mutated 5′-MSD motif was reversed back to
the wild-type form. We believe that the RV clones pos-
sess additional defect(s), other than the 5′-MSD muta-
tion, which may have been incorporated due to PCR
errors. Another limitation is that the cloned vDNAs might
not represent the genetic materials of the natural residual
virions present in plasma during sampling because of in-
herent imprecision of our multifragment amplification-
based cloning strategy. Even so, the characterization of
cloned vDNAs led us to identify the unique replication-
defective viral 5′-MSD mutation and accumulate evidence
for residual virion-synthesis and -release from highly
stable productively infected cells present in vivo. Such
stable productively infected cells constituting active reser-
voir may also release replication-competent RVs capable
of spreading infection in vivo when therapy is interrupted
[25, 28]. Other limitations of the study are that we have
cloned and characterized RVs from only one patient on
ART, and also we failed to detect the novel 5′-MSD muta-
tion in RVs of another three treated patients (mentioned
above). Studies on additional patients are required to fur-
ther verify the RVs’ characteristics and the mechanism of
their persistence in vivo. Nevertheless, the prolonged de-
tection of the defective 5′-MSD variant in plasma of a
single patient in this study, as well as the absence of drug-
resistant mutations in the virions provide, for the first
time, a strong molecular evidence for their release from a
highly stable active reservoir present in his body during
therapy. It would be interesting to examine whether any
secondary lymphoid tissues, such as lymph node or rectal
tissue, or others, in patient G possess HIV with 5′-MSD
mutation to pose as a source of RVs in plasma during sup-
pressive ART.
Conclusions
Our data, although obtained from a single patient, indi-
cate that highly stable HIV-producing cells can exist in
vivo, even in the presence of suppressive therapy. These
infected cells may pose as the previously hypothesized
active reservoir, which can release virions into plasma
either persistently or intermittently, contributing to re-
sidual plasma viremia during therapy. Should the active
reservoir harbor and release replication-competent RVs
in vivo during therapy, such viral source is expected to
spread infection quickly after therapy interruption, giv-
ing rise to viral load rebound. Thus, the elimination of
the active reservoir through new therapeutic strategies
should remain urgent in the effort of HIV-1
eradication.
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